A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium-Reference-Cited by-同舟云学术

A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium

Published:2013-07-25 Issue:11 Volume:60 Page:1868-1874
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Zorzi Alexandra P.¹,Bernstein Mark²,Samson Yvan³,Wall Donna A.⁴,Desai Sunil⁵,Nicksy Darcy⁶,Wainman Nancy⁷,Eisenhauer Elizabeth⁷,Baruchel Sylvain⁸

Affiliation:

1. Division of Hematology/Oncology, Department of Pediatrics; Children's Hospital, Western University; London ON Canada

2. Division of Pediatric Hematology/Oncology, Department of Pediatrics; Isaak Walton Killam Health Centre; Halifax NS Canada

3. Division of Hematology/Oncology; Hôpital Ste. Justine; Montreal QC Canada

4. Division of Hematology/Oncology, Department of Pediatrics; Cancer Care Manitoba; Winnipeg MB Canada

5. Division of Hematology/Oncology, Department of Pediatrics; Stollery Children's Hospital Edmonton; AB Canada

6. Department of Pharmacy; The Hospital for Sick Children; Toronto ON Canada

7. NCIC Clinical Trials Group; Kingston ON Canada

8. Division of Hematology/Oncology; Department of Pediatrics, The Hospital for Sick Children; Toronto ON Canada

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.24694/fullpdf

Reference21 articles.

1. Epigenetic modifiers: Basic understanding and clinical development;Piekarz;Clin Cancer Res,2009

2. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: Mechanisms and potential clinical implications;Schrump;Clin Cancer Res,2009

3. Functions of site-specific histone acetylation and deacetylation;Shahbazian;Annu Rev Biochem,2007

4. Histone deacetylase inhibitors: Molecular mechanisms of action;Xu;Oncogene,2007

5. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma;Glick;Cancer Res,1999

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting of human cancer stem cells predicts efficacy and toxicity of FDA-approved oncology drugs;Cancer Letters;2024-09

2. Pharmacokinetics, pharmacodynamics and safety of oral formulation (CG‐750) of ivaltinostat, a histone deacetylase inhibitor, compared to IV formulation (CG‐745);British Journal of Clinical Pharmacology;2024-01-23

3. The dual HDAC and PI3K inhibitor, CUDC‑907, inhibits tumor growth and stem‑like properties by suppressing PTX3 in neuroblastoma;International Journal of Oncology;2023-12-08

4. Dual HDAC and PI3K inhibitor CUDC-907 inhibits tumor growth and stem-like properties via suppressing PTX3 in neuroblastoma.;2023-05-15

5. Regulation of EWSR1-FLI1 Function by Post-Transcriptional and Post-Translational Modifications;Cancers;2023-01-06